Using biotechnology as a forensic foundation, Applied DNA Sciences creates unique security solutions addressing the challenges of modern commerce. Whether for supply chain security, brand protection or law enforcement applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success.
With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our plant-based DNA technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction (“PCR”).
Chief Financial Officer
Ming-Hwa Benjamin Liang, Ph.D.
Corporate Secretary and Chief Scientific Officer
Chief Information Officer
Brian Kintslinger, CFA
Applied DNA Sciences. Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Applied DNA’s performance made by the analyst(s) are theirs alone and do not represent opinions, forecasts or predictions of Applied DNA or its management. Applied DNA does not by its reference above imply its endorsement of or concurrence with such information, conclusions or recommendations. This list includes analyst(s) currently known by Applied DNA to follow the company, but may not be complete and may change as firms add or delete coverage. Applied DNA does not undertake any duty to update this information or any information provided by third parties.
Pepper Hamilton LLP
New York Times Building
620 Eighth Avenue/37th Floor
New York, New York 10018-1405
Applied DNA Sciences is not able to purchase shares on your behalf, and it is not possible for you to purchase shares directly from us. Please contact a stockbroker, bank, or independent financial advisor, who should be able to act on your behalf.
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, and our subsequent quarterly reports on Form 10-Q, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
Events and Presentations
June 6, 2017 | LD Microcap Conference | Los Angeles, NY
April 4, 2017 | The Microcap Conference | New York, NY
March 8, 2017 | Applied DNA Sciences Annual Meeting of Stockholders | Stony Brook, NY
Feb 15-16, 2017 | 2017 Disruptive Growth & Healthcare Conference | New York, NY
Online Investor Kit
Board of Directors
Applied DNA’s Board of Directors consists of individuals with proven leadership skills, broad management experience in established companies, and their reputation as independent thinkers.
With experience in fields ranging from Bioagriculture to Zoology, the company will continue to benefit from the Board’s diversity of experience and opinions.
James A. Hayward, Ph.D., Sc.D.
Chairman of the Board
John Bitzer, III
Chair of Audit Committee; Member of Compensation and Nominating Committees
Compensation Committee Member
Dr. Yacov Shamash
Chair of Compensation and Nominating Committees; Audit Committee Member
Dr. Sanford R. Simon
Nominating Committee Member